basiliximab
Phase 2- Indications
- Ulcerative colitis, Noninfectious uveitis
Company intelligence / Profile preview
Cerimon Pharmaceuticals, Inc.
South San Francisco, California, United Statesbiospace.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 2
01
Overview
Cerimon Pharmaceuticals was developing Simulect (basiliximab) for moderate-to-severe steroid-refractory ulcerative colitis and noninfectious uveitis, as well as a topical formulation of diclofenac sodium for osteoarthritis pain. The company appears to be no longer active.
- Therapeutic areas
- GastroenterologyOphthalmologyImmunologyRheumatology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Novartis Pharma AG
Beyond the preview
Go deeper on Cerimon Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cerimon Pharmaceuticals, Inc..